Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis’s Inclisiran Unscathed As Arrowhead Falls Short

But NASH Candidate Generates Interest

Executive Summary

Arrowhead’s drug has failed to match inclisiran’s performance, but its RNAi platform has other promising candidates.

You may also be interested in...



Arrowhead Gets $120m From GSK For First-In-Class NASH RNAi Candidate

GSK enters the NASH race with a mid-stage candidate while Arrowhead gets to focus its R&D spending on candidates it may bring to market itself.

$1bn Deal Boosts Takeda, Arrowhead’s Liver Disease And RNAi Ambitions

Takeda's global deal for one of US RNAi specialist's lead assets follows recent promising clinical results in serious disorder with no current therapeutic options.

Omicron Clouds Novavax’s Delayed COVID-19 Vaccine Debut

Novavax has already gained its first emergency use authorization for its COVID-19 vaccine, but doubts remain about its manufacturing and Omicron readiness.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel